Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News April 1st 2011

April 1st 2011

The surgical panacea for diabetes: time for diabetologists to discriminate facts from fiction and flights of fantasy
Bariatric surgery is an important treatment for obesity and most patients enjoy substantial improvements in coexisting type 2 diabetes (T2D). As a result of the historic failure to establish relevant long-term controlled trials, however, there is a need to separate evidence from unfounded belief (Practical Diabetes International)

IDF releases position paper on bariatric surgery
The Paper calls for bariatric surgery to be considered earlier in the treatment of eligible patients, to help stem the serious complications that can result from diabetes (IDF)

Diabetic foot problems
Inpatient management of diabetic foot problems (NICE)

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
Among patients with type 2 diabetes, use of rosiglitazone is associated with significantly higher odds of congestive heart failure, myocardial infarction, and death relative to pioglitazone in real world settings (BMJ)

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes
Evidence supports metformin as a first-line agent to treat type 2 diabetes. Most 2-drug combinations similarly reduce hemoglobin A1c levels, but some increased risk for hypoglycemia and other adverse events (Annals of Internal Medicine)

Development and validation of The Personal Diabetes Questionnaire (PDQ)
The PDQ is a useful measure of diabetes self-care behaviors and related perceptions and barriers that is reliable and valid and feasible to administer in a clinic setting (Diabetes Research and Clinical Practice)

Diabetes and Pancreatic Cancer: Chicken or Egg?
Type 2 and type 1 diabetes mellitus increase the risk of pancreatic cancer with a latency period of more than 5 years. Type 3 diabetes mellitus is an effect, and therefore a harbinger, of pancreatic cancer in at least 30% of patients (Pancreas)

Trace elements status in diabetes mellitus type 2
The results obtained suggest that antagonistic interaction between molybdenum and copper might be involved in the progress of diabetes complications (Diabetes Research and Clinical Practice)

Increased GABAergic Output in the Ventromedial Hypothalamus Contributes to Impaired Hypoglycemic Counterregulation in Diabetic Rats
These data suggest that increased VMH GABAergic inhibition is an important contributor to the absent glucagon response to hypoglycemia and the development of counterregulatory failure in type 1 diabetes (Diabetes)

Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
This three-year research collaboration, with the laboratory of Dr. Gerard Karsenty, will investigate the role of the osteoblast-secreted peptide, osteocalcin, in diabetes management (PharmaLive)

Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes
MSDC-0602 is a selective modulator of mitochondrial metabolism that modifies nutrient-sensing pathways leading to improved insulin action without direct activation of nuclear transcription factors (Therapeutics Daily)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNapp DiabetesSanofi DiabetesNovo Nordisk

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)AmgenAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership